Portage Glasgow

Portage Glasgow was a joint venture between the University of Glasgow and Portage Pharmaceuticals, focused on developing precisely targeted peptide-based therapies, particularly for disrupting protein-protein interactions in disease. The company aimed to translate academic discoveries into new therapeutics for cancer and chronic diseases, leveraging the University of Glasgow’s precision medicine expertise and Portage’s peptide delivery technology[2]. As of March 2021, Portage Glasgow Limited (along with its subsidiaries, including Portage Pharmaceuticals Limited) was divested by Portage Biotech to Juvenescence, aligning with Portage Biotech’s strategic focus on immuno-oncology[1]. There is no indication of public clinical results, suggesting programs may not have reached clinical trials before divestiture[1][2].